The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I
Abstract
PURPOSE: This AUA Guideline focuses on evaluation/counseling/management of adult patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS/METHODS: The Renal Mass and Localized Renal Cancer guideline underwent an update literature review which resulted in the 2021 amendment. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions (table 1[Table: see text]). RESULTS: Great progress has been made regarding the evaluation/management of clinically-localized renal masses. These guidelines provide updated, evidence-based recommendations regarding evaluation/counseling including the evolving role of renal-mass-biopsy (RMB). Given great variability of clinical/oncologic/functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Options for intervention (partial-nephrectomy (PN), radical-nephrectomy (RN), and thermal-ablation (TA)) are reviewed including recent data about comparative-effectiveness/potential morbidities. Oncologic issues are prioritized while recognizing the importance of functional-outcomes for survivorship. Granular criteria for RN are provided to help reduce overutilization of RN while also avoiding imprudent PN. Priority for PN is recommended for clinical T1a lesions, along with selective utilization of TA, which has good efficacy for tumors≤3.0 cm. Recommendations for genetic-counseling have been revised and considerations for adjuvant-therapies are addressed. Active-surveillance and follow-up after intervention are discussed in an adjunctive article. CONCLUSION: Several factors require consideration during counseling/management of patients with clinically-localized renal masses including general health/comorbidities, oncologic-considerations, functional-consequences, and relative efficacy/potential morbidities of various management-strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D. D. E., Hostetter, T. H., Lameire, N., & Eknoyan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00365.x · Cited by 3,946
Charles, C., Gafni, A., & Whelan, T. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00145-8 · Cited by 2,333
Guideline for Management of the Clinical T1 Renal Mass
Campbell, S. C., Novick, A. C., Belldegrun, A., Blute, M. L., Chow, G. K., Derweesh, I. H., Faraday, M. M., Kaouk, J. H., Leveillee, R. J., Matin, S. F., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.004 · Cited by 1,831
Self-citationEuropean Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bensalah, K., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.011 · Cited by 1,456
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Renal Mass and Localized Renal Cancer: AUA Guideline
Campbell, S., Uzzo, R. G., Allaf, M. E., Bass, E. B., Cadeddu, J. A., Chang, A., Clark, P. E., Davis, B. J., Derweesh, I. H., Giambarresi, L., et al. (2017) · Journal of Urology · doi:10.1016/j.juro.2017.04.100 · Cited by 1,242
Self-citationFRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Solid Renal Tumors: An Analysis of Pathological Features Related to Tumor Size
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2003) · Journal of Urology · doi:10.1097/01.ju.0000095475.12515.5e · Cited by 1,080
Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003) · Cancer · doi:10.1002/cncr.11234 · Cited by 837
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Cited by
Renal Cell Carcinoma: A Review
Rose, T. L., & Kim, W. Y. (2024) · JAMA · doi:10.1001/jama.2024.12848 · Cited by 374
Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J., & Abel, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871252 · Cited by 28
Metadata
- Authors
- Campbell, S. C., Clark, P. E., Chang, S. S., Karam, J. A., Souter, L., & Uzzo, R. G.
- Venue
- Journal of Urology
- Published
- 2021-08
- Volume
- 206
- Issue
- 2
- Pages
- 199-208
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W3168645700
- Cited by
- 775
- References
- 41
- FWCI
- 61.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. https://app.cochat.ai/papers/10.1097/ju.0000000000001911
- The paper
- Campbell, S. C., Clark, P. E., Chang, S. S., Karam, J. A., Souter, L., & Uzzo, R. G. (2021). Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. Journal of Urology. https://doi.org/10.1097/ju.0000000000001911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.